Literature DB >> 11348455

Early- and late-stage Kaposi's sarcoma-derived cells but not activated endothelial cells can invade de-epidermized dermis.

T Simonart1, C Degraef, R Mosselmans, P Hermans, Y Lunardi-Iskandar, J C Noel, J P Van Vooren, D Parent, M Heenen, P Galand.   

Abstract

Whether Kaposi's sarcoma is a true neoplasm or a reactive endothelial cell outgrowth triggered by inflammatory cytokines remains unclear. In this study, we investigated the differential invasive properties of activated endothelial cells and Kaposi's sarcoma cells in a model of de-epidermized dermis, supplying the cells with matrix barriers similar to those found in vivo. Cells derived from early "patch-stage" and from late "nodular-stage" Kaposi's sarcoma lesions exhibited similar invasive properties, which indicates that cells with an invasive potential are present in the early stages of tumor development. Slow accumulation of the cells into the extracellular matrix, together with a low proliferation index and with expression of anti-apoptotic proteins, suggest that the progression of Kaposi's sarcoma may be related to escape from cell death rather than to increased proliferation. The Kaposi's sarcoma-Y1 cell line, which is tumorigenic in nude mice, also exhibited invasive properties. By contrast to the Kaposi's sarcoma-derived spindle cells, however, which were scattered between the collagen bundles, the Kaposi's sarcoma-Y1 cell population had a higher proliferation index and displayed a multilayer arrangement. Inflammatory cytokines and Kaposi's sarcoma cell supernatant could activate and stimulate the growth of human dermal microvascular endothelial cell, but could not induce their invasion in this model, showing that activated endothelial cells do not fit all the requirements to traverse the various barriers found in the dermal extracellular matrix. These results confer to Kaposi's sarcoma cells a tumor phenotype and suggest that the in vivo dominant endothelial cell population represents a reactive hyperplasia rather than the true tumor process.

Entities:  

Mesh:

Year:  2001        PMID: 11348455     DOI: 10.1046/j.1523-1747.2001.01319.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  Kaposi's sarcoma-associated herpesvirus infection promotes differentiation and polarization of monocytes into tumor-associated macrophages.

Authors:  Natarajan Bhaskaran; Santosh K Ghosh; Xiaolan Yu; Sanhai Qin; Aaron Weinberg; Pushpa Pandiyan; Fengchun Ye
Journal:  Cell Cycle       Date:  2017-07-27       Impact factor: 4.534

2.  Human herpesvirus 8 viral FLICE-inhibitory protein retards cell proliferation via downregulation of Id2 and Id3 expression.

Authors:  Yi-Fen Wang; Lin-Yu Wang; Yi-Ling Li; Huey-Wen Shyu; Yee-Hsuan Chiou; Miao-Chen Chou; Kuan-Hua Lin; Ming-Hong Tai; Chang-Yu Chen
Journal:  Mol Cell Biochem       Date:  2010-05-29       Impact factor: 3.396

3.  Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death.

Authors:  Mathias Thurau; Gaby Marquardt; Nathalie Gonin-Laurent; Kristina Weinländer; Elisabeth Naschberger; Ramona Jochmann; Khaled R Alkharsah; Thomas F Schulz; Margot Thome; Frank Neipel; Michael Stürzl
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

4.  Cultured Kaposi's sarcoma tumor cells exhibit a chemokine receptor repertoire that does not allow infection by HIV-1.

Authors:  T Simonart; C Debussher; C Liesnard; L Debaisieux; M L Delforge; A de Lavareille; P Hermans; J P Van Vooren; P Stordeur
Journal:  BMC Dermatol       Date:  2001-07-24

5.  The inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells.

Authors:  Darya A Haas; Kiran Bala; Guntram Büsche; Magdalena Weidner-Glunde; Susann Santag; Semra Kati; Silvia Gramolelli; Modester Damas; Oliver Dittrich-Breiholz; Michael Kracht; Jessica Rückert; Zoltan Varga; György Keri; Thomas F Schulz
Journal:  PLoS Pathog       Date:  2013-11-07       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.